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Diarrhoea is a common problem affecting between 20% and
60% of travellers,1 particularly those visiting low and middle
income countries. Travellers’ diarrhoea is defined as an increase
in frequency of bowel movements to three or more loose stools
per day during a trip abroad, usually to a less economically
developed region. This is usually an acute, self limiting
condition and is rarely life threatening. In mild cases it can affect
the enjoyment of a holiday, and in severe cases it can cause
dehydration and sepsis. We review the current epidemiology of
travellers’ diarrhoea, evidence for different management
strategies, and the investigation and treatment of persistent
diarrhoea after travel.
Who is at risk?
Variation in incidence1 2 may reflect the degree of risk for
different travel destinations and dietary habits while abroad.
Destinations can be divided into low, medium, and high risk
(see box 1). Rates of diarrhoea are likely to correlate closely
with the quality of local sanitation.
Backpackers have roughly double the incidence of diarrhoea
compared with business travellers.4 Travel in cruise ships is
associated with large outbreaks of viral and bacterial
gastroenteritis.5 General advice is to avoid eating salads,
shellfish, and uncooked meats. There is no strong evidence that
specific dietary measures reduce incidence of diarrhoea, but
studies examining this are likely to be biased by imperfect recall
of what was eaten.6 Risk factors for travellers’ diarrhoea are
listed in box 2.
What are the most important causes of
travellers’ diarrhoea?
Most studies report a failure to identify the causative pathogen
in between 40% and 70% of cases.10 This includes multicentre
studies based in high prevalence settings (that is, during
travel).3-12 This low diagnostic yield is partly due to delay in
obtaining samples and partly due to the insensitivity of
laboratory investigations. Older studies did not consistently
attempt to identify enteroaggregative Escherichia coli (EAEC),
and surveillance studies vary in reporting of other E coli species.3
Where a pathogen is identified, bacteria are the commonest
cause of acute travellers’ diarrhoea, with the remainder being
caused by norovirus, rotavirus, or similar viruses (see table 1⇓).
Protozoa such asGiardia lamblia can also cause acute diarrhoea,
but they are more often associated with persistent diarrhoea,
lasting more than two weeks. Cyclospora catayensis, another
protozoan cause of diarrhoea, was identified in an increased
number of symptomatic travellers returning fromMexico to the
UK and Canada in 2015.13
Table 1⇓ illustrates overall prevalence of causative agents in
returning travellers with diarrhoea. However relative importance
varies with country of exposure. Rates of enterotoxigenic E coli
(ETEC) are lower in travellers returning from South East Asia
than in those returning from South Asia, sub-Saharan Africa,
and Latin America, whereas rates of Campylobacter jejuni are
higher. Norovirus is a more common cause in travellers to Latin
America and sub-Saharan Africa, and Giardia lamblia and
Entamoeba histolytica are more common in travellers to South
and South East Asia.10
The importance of enterotoxigenicE coli as a cause for diarrhoea
in travellers returning from Latin America has been decreasing
over the past four decades.10 A large scale analysis of
EuroTravNet surveillance data shows increasing incidence of
Campylobacter jejuni infection in travellers returning from
India, Thailand, and Pakistan.2
How does travellers’ diarrhoea present?
Most episodes of travellers’ diarrhoea start during the first week
of travel, with the peak incidence on the second or third day
after arrival.8 14
Typically diarrhoea caused by enterotoxigenic E coli (“turista”)
is watery and profuse, and preceded by abdominal cramps,
nausea, and malaise. Symptoms are not a reliable guide to
aetiology, but upper gastrointestinal manifestations such as
bloating and belching tend to predominate withGiardia lamblia,
while colitic symptoms such as urgency, bloody diarrhoea, and
cramps are seen more often with Campylobacter jejuni and
Shigella spp.
Most episodes will last between one and seven days, with
approximately 10% lasting for longer than one week, 5% lasting
more than two weeks, and 1% lasting more than 30 days.8
During the illness, few patients will be severely incapacitated
(in one large prospective cohort about 10% of 2800 participants
were confined to bed or consulted a physician), but planned
activities are often cancelled or postponed.8
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What you need to know
• Enterotoxic Escherichia coli (ETEC) is the most common cause of acute travellers’ diarrhoea globally
• Chronic (>14 days) diarrhoea is less likely to be caused by bacterial pathogens
• Prophylactic antibiotic use is only recommended for patients vulnerable to severe sequelae after a short period of diarrhoea, such as
those with ileostomies or immune suppression
• A short course (1-3 days) of antibiotics taken at the onset of travellers’ diarrhoea reduces the duration of the illness from 3 days to
1.5 days
• Refer patients with chronic diarrhoea and associated symptoms such as weight loss for assessment by either an infectious diseases
specialist or gastroenterologist
Methods
We searched PubMed and Cochrane Library databases for “travellers’ diarrhoea,” and “travel-associated diarrhoea,” to identify relevant
articles, which were added to personal reference collections and clinical experience. Where available, systematic reviews and randomised
controlled trials were preferentially selected.
Box 1: Risk of travellers’ diarrhoea according to destination1 3
High risk destinations
• South and South East Asia*
• Central America*
• West and North Africa*
• South America
• East Africa
Medium risk
• Russia
• China
• Caribbean
• South Africa
Low risk
• North America
• Western Europe
• Australia and New Zealand
*Regions with particularly high risk of travellers’ diarrhoea
Box 2: Factors increasing risk of travellers’ diarrhoea4-9
By increased dietary exposure
• Backpacking
• Visiting friends and family
• All-inclusive holidays (such as in cruise ships)
By increased susceptibility to an infectious load
• Age <6 years
• Use of H2 receptor antagonists and proton pump inhibitors
• Altered upper gastrointestinal anatomy
• Genetic factors (blood group O predisposes to shigellosis and severe cholera infection)
How can travellers’ diarrhoea be
prevented?
Several controlled trials have failed to demonstrate an impact
of food and drink hygiene advice on rates of diarrhoea.15
However, the clear food-related source of most diarrhoeal
pathogensmeans that general consensus among travel physicians
is to continue to recommend boiling water, cooking food
thoroughly, and peeling fruit and vegetables.6Other basic advice
includes avoiding ice, shellfish, and condiments on restaurant
tables, using a straw to drink from bottles, and avoiding salads
and buffets where foodmay have been unrefrigerated for several
hours. Travellers should be advised to drink bottled water where
available, including in alcoholic drinks, as alcohol does not
sterilise non-bottled water. If bottled water is not available,
water can be purified by boiling, filtering, or use of chlorine
based tablets.16 There is someweak evidence that use of alcohol
hand gel may reduce diarrhoea rates in travellers,17 but, based
on studies in non-travellers, it is reasonable to strongly
encourage travellers to adhere to good hand hygiene measures.
Two recent systematic reviews estimated hand washing with
soap reduces the risk of diarrhoeal illness by 30-40%.18 19
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When is antibiotic prophylaxis
recommended?
For most travellers antibiotic chemoprophylaxis (that is, daily
antibiotics for the duration of the trip) is not recommended.
While diarrhoea is annoying and distressing, severe or long term
consequences from a short period of diarrhoea are rare, and
routine use of chemoprophylaxis would create a large tablet
burden and expose users to possible adverse effects of antibiotic
therapy such as candidiasis and diarrhoea associated with
Clostridium difficile.
Chemoprophylaxis should be offered to those with severe
immune suppression (such as from chemotherapy for
malignancy or after a tissue transplant, or advanced HIV
infection), underlying intestinal pathology (inflammatory bowel
disease, ileostomies, short bowel syndrome), and other
conditions such as sickle cell disease or diabetes where reduced
oral intake may be particularly dangerous (table 2⇓).22 These
patient groups may be unable to tolerate the clinical effects and
dehydration associated with even mild diarrhoea, or the
consequences of more invasive complications such as
bacteraemia. For such patients, it is important to discuss the
benefits of treatment aimed at preventing diarrhoea and its
complications against the risks of antibiotic associated diarrhoea
and other side effects. If antibiotics are prescribed then
consideration should be given to any possible interactions with
other medications that the patient is taking.
A small comparative study in US soldiers showed that malaria
prophylaxis with daily doxycycline has the added benefit of
reducing rates of travellers’ diarrhoea caused by enterotoxigenic
E coli and Campylobacter jejuni.23
Do vaccines have a role in prevention of
travellers’ diarrhoea?
Vaccines have been developed and licensed against Salmonella
typhi, Vibrio cholerae, and rotavirus—all with reasonable
efficacy. However, unlike enterotoxigenic E coli, none of these
is a major cause of travellers’ diarrhoea, and only vaccines
against S typhi are recommended for most travellers to endemic
settings. Phase 3 trials of enterotoxigenic E coli toxin vaccines
have been undertaken but have failed to demonstrate efficacy.24
Studies suggest vaccines against enterotoxigenic E coli would
have a major public health impact in high burden countries, and
further candidate vaccines are in development.25
What are the options for self administered
treatment?
Table 3⇓ summarises the options for self treatment.
Anti-motility agents and oral rehydration
therapy
For most cases of travellers’ diarrhoea, oral rehydration is the
mainstay of treatment. This can be achieved with clear fluids
such as diluted fruit juice or soups. Young children, elderly
people, and those at greater risk from dehydration (that is, those
with medical comorbidities) are recommended to use oral
rehydration salts (or a mixture of six level teaspoons of sugar
and half a teaspoon of salt in a litre of clean water if rehydration
salts are unavailable) (see http://rehydrate.org/rehydration/index.
html).
Anti-motility agents such as loperamide may be appropriate for
mild symptoms, or where rapid cessation of diarrhoea is
essential. Case reports of adverse outcomes such as intestinal
perforation suggest anti-motility agents should be avoided in
the presence of severe abdominal pain or bloody diarrhoea,
which can signify invasive colitis.26 Systematic review of several
randomised controlled trials have demonstrated a small benefit
from taking bismuth subsalicylate, but this has less efficacy in
reducing diarrhoea frequency and severity than loperamide.27
Antibiotics
Symptomatic treatment is usually adequate and reduces
antibiotic use. However, some travellers will benefit from rapid
cessation of diarrhoea, particularly if they are in a remote area
with limited access to sanitation facilities or healthcare. Several
systematic reviews of studies comparing antibiotics (including
quinolones, azithromycin, and rifaximin) against placebo have
shown consistent shortening of the duration of diarrhoea to
about one and a half days from around three days.28-30 Short
courses (one to three days) of antibiotics are usually sufficient
to effect a cure.30
For some people travelling to high and moderate risk areas (see
box 1) it will be appropriate to provide a short course of a
suitable antibiotic, with advice to start treatment as soon as they
develop diarrhoea and to keep well hydrated. Choice of
antibiotic will depend on allergy history, comorbidities,
concomitant medications, and destination. Avoid quinolones
for both prophylaxis and treatment of travellers to South East
and South Asia as levels of quinolone resistance are high.31
Azithromycin remains effective in these areas, but resistance
rates are likely to increase.
A meta-analysis of nine randomised trials showed that the
addition of loperamide to antibiotic treatment (including
azithromycin, ciprofloxacin, and rifamixin) resulted in
statistically significantly higher rates of cure at 24 and 48 hours
compared with antibiotic alone.32 Travellers can be advised to
add loperamide to their antibiotic treatment to reduce the time
to symptomatic improvement as long as there are no features
of invasive colitis such as severe pain, high fever, or blood
visible in the diarrhoea.30 If any of these symptoms develop,
travellers are advised to seek medical advice immediately.
Returned travellers with persistent
diarrhoea
Most bacterial causes mentioned do not cause persistent
diarrhoea in immune competent adults. Travellers with diarrhoea
persisting beyond 14 days may present in primary or secondary
care on their return and require assessment for other underlying
causes of persistent diarrhoea.
Table 4⇓ lists the important clinical history and symptoms that
can point to the underlying cause.
What investigations should be sent?
For diarrhoeal symptoms that persist beyond 14 days following
travel (or sooner if there are other concerning features such as
fever or dysentery), offer patients blood tests for full blood
count, liver and renal function, and inflammatory markers; stool
samples for microscopy and culture; and examination for ova,
cysts, and parasites. Historically, advice has been to send three
stool samples for bacterial culture, but this is unlikely to increase
the diagnostic yield. Instead, stool microscopy can be used to
distinguish inflammatory from non-inflammatory causes: a
small observational study found presence of faecal leucocytes
was predictive of a positive bacterial stool culture.33Yield from
stool culture may be increased by dilution of the faecal sample,
and the introduction of molecular tests such as polymerase chain
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reaction (PCR) for common gastrointestinal pathogens such as
Campylobacter sppmay decrease turnaround times and increase
yield.34
Additional tests should be offered according to symptoms and
risk (table 4⇓). If the patient has eosinophilia and an appropriate
travel history, the possibility of schistosomiasis, strongyloides,
and other helminthic infections should be considered. While
schistosomiasis can rarely cause diarrhoea in the context of
acute infection, serologymay be negative in the first fewmonths
of the illness.
Imaging is required only if the patient has signs of severe colitis
or local tenderness, in which instances toxic megacolon,
inflammatory phlegmon, and hepatic collections should be
excluded. Patients with severe colitis or proctitis may need joint
assessment with gastroenterology and consideration of
endoscopy, or laparotomy if perforation has occurred.
Where infectious and non-infectious causes have been
appropriately excluded, the most likely diagnosis is
post-infectious irritable bowel syndrome, although diarrhoea
can also herald underlying bowel pathology and anyone with
red flags for malignancy should be referred by the appropriate
pathway for assessment. Post-infectious irritable bowel
syndrome has an incidence of around 30% after an acute episode
of travel associated gastroenteritis.35 36 It is more commonly a
sequela of prolonged episodes of diarrhoea or diarrhoea
associated with fever and bloody stools.36 There is weak
evidence from small randomised trials suggesting that exclusion
of foods high in fermentable carbohydrates (FODMAP) may
be helpful.37 Exclusion of dietary lactose and use of loperamide,
bile acid sequestrants, and probiotics can also be tried, but there
is limited evidence for long term benefit.35-38
How should giardiasis be managed?
The most common pathogen identified in returning travellers
with chronic diarrhoea is Giardia lamblia, particularly among
people returning from South Asia.39 Use of G lamblia PCR
testing has increased detection,40which potentially will identify
infection in some patients previously labelled as having
post-infectious irritable bowel syndrome and in those whose
diarrhoea may have been attributed to non-pathogenic protozoa.
Most patients respond to 5-nitroimidazoles (a systematic review
of a large number of trials has shown similar cure rates with
tinidazole 2 g once only or metronidazole 400 mg three times
daily for five days41), but refractory cases are increasingly
common and require investigation, identification of underlying
risk factors, and repeated treatment (various antimicrobials have
been shown to be effective but may have challenging risk
profiles). .
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Questions for future research
• What is the justification for using antibiotics to treat a usually self limiting illness, in the wider context of rising levels of global antimicrobial
resistance rates? What is the clinical impact of resistant enterobacteriaciae found in stool samples from returning travellers?42 43
• To what extent do host genetic factors increase susceptibility to gastrointestinal pathogens, and can this help to identify at risk
populations and tailor treatments to individual patients?
• What is the long term efficacy of new pharmacological treatments such as selective serotonin reuptake inhibitors and rifaximin in
post-infectious irritable bowel syndrome?
Tips for non-specialists
• Include consideration of chemoprophylaxis for high risk individuals in pre-travel assessment
• Advise all travellers on hygiene measures (such as hand washing and food consumption) and symptom management of diarrhoea
• Avoid quinolones for prophylaxis or treatment in travellers to South East and South Asia
• Where diarrhoea persists beyond 14 days, consider investigations to rule out parasitic and non-infectious causes. The presence of
white blood cells on stool microscopy indicates an inflammatory cause
Additional educational resources
Resources for patients
• National Travel Health Network and Centre (NaTHNaC): http://travelhealthpro.org.uk/travellers-diarrhoea/
Provides pre-travel advice, as well as links to country-specific advice
• Fit for Travel: www.fitfortravel.nhs.uk/advice/disease-prevention-advice/travellers-diarrhoea.aspx
Provides similar pre-travel advice on hygiene and disease prevention
• Patient.co.uk: http://patient.info/doctor/travellers-diarrhoea-pro
Has patient leaflets and more detailed information about investigation and management of travellers’ diarrhoea
Resources for healthcare professionals
• Centers for Disease Control and Prevention yellow book: http://wwwnc.cdc.gov/travel/yellowbook/2016/the-pre-travel-consultation/
travelers-diarrhea
Provides a guide to pre-travel couselling
• Rehydration Project website: http://rehydrate.org/rehydration/index.html
Has additional information about non-pharmacological management of diarrhoea
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Tables
Table 1| Frequency of pathogens causing travellers’ diarrhoea23101112
Clinical featuresPrevalence*Pathogen
Bacterial
Acute watery diarrhoea, abdominal cramping. Fever less common12-34%Enterotoxigenic Escherichia coli (ETEC)
Acute watery diarrhoea1-24%Enteroaggregative E coli (EAEC)
Acute diarrhoea, abdominal cramps, bloody stools, fever8-32%Campylobacter jejuni
Acute diarrhoea, fever, vomiting, abdominal cramps4-9%Salmonella spp
Acute diarrhoea, abdominal cramps, bloody stools, fever, tenesmus. Features may persist2-14%Shigella spp
Acute watery diarrhoea, fever, abdominal cramps<5%Aeromonas spp
Acute lower abdominal pain, bloody stools, tenesmus, fever<5%Plesiomonas spp
Acute profuse watery diarrhoea<1%Vibrio cholerae
Viral
Acute watery diarrhoea, vomiting7-9%Norovirus
Acute watery diarrhoea, abdominal cramps, vomiting, low grade fever13-17%Rotavirus
Parasitic
Chronic diarrhoea, may be steatorrhoea, flatus, distension1-6%Giardia lamblia
Watery diarrhoea, sometimes abdominal cramps, may be prolonged1-3%Cryptosporidium spp
Acute lower abdominal pain, bloody stools, tenesmus, fever1-4%Entamoeba histolytica
*Percentage of all cases of diarrhoea with identified cause in these studies
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Table 2| Antibiotic chemoprophylaxis options for immunosuppressed or other high risk travellers
Percentage protection6-21DoseAntibiotic
80-100%500 mg once dailyCiprofloxacin
75-95%400 mg once dailyNorfloxacin
72-77%200 mg once or twice dailyRifaximin
62-65%2 tablets four times dailyBismuth subsalicylate
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Table 3| Summary of self treatment choices
TreatmentSeverity of symptoms
Liberal intake of clear fluids.
Oral rehydration salts for young children, elderly people, and travellers with medical comorbidities
All cases
Loperamide: 4 mg taken immediately, then 2 mg for each loose stool to a maximum of 16 mg per dayMild symptoms (1-2 unformed stools per 24 hours)
Moderate symptoms:
Ciprofloxacin: 500 mg twice daily for three daysSouth and Central America, Africa
Azithromycin: 1 g single dose, or 500 mg daily for three days
Rifaximin: 200 mg three times daily for three days
South and South East Asia
Seek local medical assistance
Avoid loperamide
High fever, severe abdominal pain, bloody diarrhoea
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Table 4| Assessment of chronic diarrhoea
CauseSymptoms
Giardia lamblia, microsporidiosisBloating, nausea, belching
Salmonella typhi or S paratyphi, malariaFever
Entamoeba histolytica, inflammatory bowel diseaseBloody diarrhoea
Inflammatory bowel disease, reactive arthritis after colitisArthropathy, uveitis
Malabsorption, Giardia lamblia, lactose intoleranceGreasy, malodorous stools
History
HIV, Shigella spp, Lymphogranuloma venereum, Giardia lambliaUnprotected sexual intercourse
Clostridium difficileAntibiotic use
Coeliac disease, inflammatory bowel disease, irritable bowel diseaseSymptoms before travel
Hyperthyroidism, coeliac diseaseAutoimmune disease
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